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Accounting for Heterogeneity
in Relative Treatment Effects
for Use in Cost-Effectiveness Models
and Value-of-Information Analyses
Nicky J. Welton, Marta O. Soares, Stephen Palmer, Anthony E. Ades,
David Harrison, Manu Shankar-Hari, Kathy M. Rowan
Cost-effectiveness analysis (CEA) models are routinely
used to inform health care policy. Key model inputs
include relative effectiveness of competing treatments, typ-
ically informed by meta-analysis. Heterogeneity is ubiqui-
tous in meta-analysis, and random effects models are
usually used when there is variability in effects across stud-
ies. In the absence of observed treatment effect modifiers,
various summaries from the random effects distribution
(random effects mean, predictive distribution, random ef-
fects distribution, or study-specific estimate [shrunken or
independent of other studies]) can be used depending on
the relationship between the setting for the decision (popu-
lation characteristics, treatment definitions, and other con-
textual factors) and the included studies. If covariates have
been measured that could potentially explain the heteroge-
neity, then these can be included in a meta-regression
model. We describe how covariates can be included in
a network meta-analysis model and how the output from
such an analysis can be used in a CEA model. We outline
a model selection procedure to help choose between com-
peting models and stress the importance of clinical input.
We illustrate the approach with a health technology assess-
ment of intravenous immunoglobulin for the management
of adult patients with severe sepsis in an intensive care set-
ting, which exemplifies how risk of bias information can be
incorporated into CEA models. We show that the results of
the CEA and value-of-information analyses are sensitive to
the model and highlight the importance of sensitivity
analyses when conducting CEA in the presence of heteroge-
neity. The methods presented extend naturally to heteroge-
neity in other model inputs, such as baseline risk. Key
words: cost-effectiveness analysis; Bayesian meta-analysis;
value of information. (Med Decis Making 2015;35:
608–621)
Cost-effectiveness analysis (CEA) models are rou-tinely used to inform health care policy deci-
sions between health care options.1 Relative
treatment effects for effectiveness outcomes are
among the key input parameters to CEA models.
For policy decisions to reflect the evidence avail-
able, it is important that the relative effect inputs
and their uncertainty are reflected appropriately in
CEA models. CEA models are also used in value-
of-information analyses that explore the need for,
and optimal design of, new research studies.2
Relative treatment effects are typically obtained
from meta-analyses or network meta-analyses (also
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termed mixed treatment comparisons)3–5 of all the
available relevant randomized controlled trials
(RCTs) that report the outcomes of interest. Ideally,
all the RCTs estimate a common true treatment effect,
and the only reason for differences between study esti-
mates is sampling error. In this case, a fixed effect (FE)
model can be used to deliver a single pooled estimate
for each treatment comparison of interest. However,
more often than not, there is additional variability
between studies due to differences in inclusion criteria
and/or trial conduct, such that the RCTs estimate dif-
ferent true treatment effects. It is then usually assumed
that the study-specific true relative effects are similar in
the sense that they can be described as coming from
a common random effects (RE) distribution (usually
assumed Normal).6 The relative effect that is reported
is usually the mean of this distribution, although the
predictive distribution or the entire RE distribution
has been proposed,7,8 and some alternative approaches
have been suggested recently in a short letter.9
Heterogeneity in relative effects canarise as a result
of an imbalance in treatment effect–modifying
patient characteristics across studies and/or in
study-level parameters. If study-level parameters
have been reported, then they can be included as
covariates in ameta-regressionmodel.3,6,10,11 Ideally,
to avoid ecological bias,12 individual patient data are
required to explore the impact of imbalance in
patient-level characteristics, although for binary out-
comes reported by subgroup, then aggregate-level
data are sufficient, which is a simple example of
meta-regression. Inclusions of treatment effect–
modifyingcovariates areexpected to lead toa reduction
in heterogeneity and, in the extreme case, will elimi-
nate heterogeneity entirely, reducing an RE model to
an FEmodel. Theremay bemany covariates that could
potentially be included in a meta-regression, and
a strategy is required to choose between models.
Where there is evidence of heterogeneity, careful
thought needs to be given as to the most appropriate
input to use in a CEA model. If subgroups have
been identified, and it is acceptable to make different
treatment recommendations in different subgroups,
CEA models can be developed separately for each
subgroup.13 The results from a CEA may be sensitive
to the choice of which covariate model is selected,
and so a structured approach to model selection is
desirable. For example, an RE model with no covari-
ateswill result in less precise relative treatment effect
estimates than those fromanREmodel inwhich some
of the heterogeneity is explained by covariates. RE
models can be summarized and interpreted in a vari-
ety of ways,7–9 and this needs to be reflected in a CEA
model. Again, results from a CEA may be sensitive to
this choice.9
In this article, we describe a general framework to
model and account for heterogeneity in relative effect
inputs to CEA models and set out a general strategy
for model selection. Although we focus on relative
treatment effects, the ideas extend naturally to other
model inputs that exhibit heterogeneity.We illustrate
the approaches with a recent health technology
assessment of intravenous immunoglobulin (IVIG)
for themanagement of adult patients with severe sep-
sis and septic shock.14 This case study exemplifies
how risk of bias information can be incorporated
into CEA models that, to our knowledge, has not
been addressed in the literature previously.
METHODS
Net Benefit
Weassume there is a cost-effectivenessmodelwith
a net benefit function NB k;ddeck ; u
 
that depends on
ddeck , the relative effect of treatment k relative to treat-
ment 1 in the target setting for the decision, and other
input parameters u, which includes treatment costs,
natural history parameters such as baseline risk,
resource use costs, adverse events, and utilities. By
target ‘‘setting’’ for the decision, we include the
patient population characteristics, treatment defini-
tions, and other contextual factors. There may be
uncertainty in all of the parameter inputs to the net
benefit function, which need to be averaged over to
obtain the expected net benefit, on which to base
decisions.We assume that there is only a single effec-
tiveness outcome relevant to the decision model.
Meta-Analysis Models in the Absence of Covariates
In all that follows, we assume that relative effects
are modeled on an appropriate scale (e.g., log-odds
ratios for binary observations). When there are two
treatments being compared, a pairwise FE meta-
analysis model assumes that the true relative treat-
ment effects, dj, from study j are equal, dj5d2, where
d2 is the pooled mean effect of treatment 2 relative to
treatment 1. For a pairwise RE meta-analysis model,
the dj are assumed to come from a commondistribution,
for example, for a Normal RE model, dj;Nðd2; t2Þ,
where d2 is the mean of the RE distribution and t
2 is
the between-study variance in treatment effects.
When there are several competing treatments, rel-
ative effect estimates can be obtained from a network
meta-analysis4:
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Fixed Effect Model : dj;k;b5dk  db; d15 0
RandomEffectsModel : dj;k;b;Nðdk  db; t2Þ; d15 0
ð1Þ
where dj; k; b is the estimated effect of treatment k in
study j relative to the baseline (lowest numbered)
treatment b for that study, and dk is the mean effect
of treatment k relative to treatment 1. In the REmodel,
the between-study variance parameter is assumed the
same for every treatment comparison (homogeneous
variance assumption). If there are only two treat-
ments, then equation (1) reduces to a standard pair-
wise meta-analysis.4
Meta-Analysis Inputs to CEA in the Absence
of Covariates
Note that in all that follows, parameter inputs are
estimatedwith uncertainty, and this uncertainty needs
to be averaged over to obtain expected net benefit.
For an FE model, assuming that the treatment
effect in the target setting for the decision is no differ-
ent from those in the studies that make up the (net-
work) meta-analysis, then the ddeck are expected to
be equal to the pooled treatment effect(s) from the
(network) meta-analysis, so that the relevant effec-
tiveness inputs to the CEA model and net benefit
for the decision population are
ddeck 5dk and NB
decðk;dk ; uÞ5NBðk;dk ; uÞ: ð2Þ
There are several possible approaches to summa-
rize an RE model to provide inputs to a CEA model,
which depend on our interpretation of the heteroge-
neity in the studies included in the (network) meta-
analysis and how this relates to the target setting for
the decision.9
(a) Random effects mean. The most commonly used
approach is to use the mean of the RE distribution
as the input for the CEA model, so that
ddeck 5dk and NB
decðk;dk ; uÞ5NBðk;dk ; uÞ: ð3Þ
This assumes that the target setting for the decision is
exactly equal to the average setting from the studies
included in the (network) meta-analysis. This is
unlikely to be the case in practice. One possible sce-
nario when equation (3) might be appropriate is if the
cause of theheterogeneity is due solely to bias resulting
from flaws in study conduct but that the bias across
studies is centered on 0. Then the RE mean represents
the treatment effect in an unbiased study.
(b) Predictive distribution. Due to the difficulty in
interpreting the RE mean, the predictive distribu-
tion has been proposed as a more realistic way to
characterize the uncertainty in the treatment effect
we may expect to see in the future. A prediction
dpredk is drawn from the RE distribution,
dpredk ;Nðdk; t2Þ. dpredk has the same central estimate
as the RE mean, dk, but is less precise, because it
reflects the uncertainty as to where a randomly
selected study setting might lie in the RE distribu-
tion, aswell as the uncertainty in the RE parameters
dk and t. The precision of d
pred
k therefore decreases
with increasing heterogeneity. In this case:
ddeck 5d
pred
k and NB
decðk;dpredk ; uÞ5NBðk;dpredk ; uÞ: ð4Þ
This assumes that the target setting for the decision
is ‘‘similar’’ to those in the studies included in the
(network) meta-analysis in the sense that ddeck comes
from the same distribution of treatment effects, but
we do not know where in the RE distribution ddeck
lies. This may often be reasonable, but it may be
the case that the target setting for the decision is
more closely related to a subset or a single study in
the (network) meta-analysis, in which case the pre-
dictive distribution will lead to biased and impre-
cise estimates.
(c) Independent study-specific estimate. If we con-
sider the target setting for the decision to be repre-
sented by a single study population, jdec, and
information obtained from all other study popula-
tions are irrelevant, then we use the effect estimate
from that study alone (not from a meta-analysis) as
the input to the CEA, so that
ddeck 5djdec ;k and NB
decðk;djdec ;k ; uÞ5NBðk;djdec ;k ; uÞ: ð5Þ
This might be the case if all studies except one are
deemed to be at high risk of bias, and if this is the
cause of the heterogeneity, then we may want to
only use the results from the study not at high risk
of bias. Note, however, that this approach is limited,
as it can only be used for treatment comparisons that
have been included in study jdec.
If a subset of the studies are considered representa-
tive, then either the pooled estimate from an FE
model on that subset of studies or the predictive dis-
tribution from an RE model on that subset of studies
may be used.
(d) Shrunken study-specific estimate. If we consider
the target setting for the decision to be ‘‘similar
to’’ those in the studies included in the (network)
WELTON AND OTHERS
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meta-analysis (as for the predictive distribution),
but it is most closely represented by a single study
population, jdec, thenwemaywant to use the study-
specific estimate for study jdec estimated from an RE
model, djdec; k;1. This estimate, known as a shrunken
estimate, will be drawn in toward the RE mean
(depending on the relative size of the study and
the degree of heterogeneity) and will be more pre-
cisely estimated than the study estimate alone,
because it is ‘‘borrowing strength’’ from the other
study estimates. Then the input to the CEAmodel is
ddeck 5 djdec ; k; 1NB
decðk; djdec ;k;1; uÞ5NBðk; djdec ;k; 1; uÞ: ð6Þ
If study jdec does not include treatment c, we can
apply the consistency equations (4), dk; c5dk  dc,
to obtain the study-specific shrunken effect of treat-
ment c compared with treatment 1:
djdec ; c;15 djdec ; k; b  ðdk  dbÞ1dc: ð7Þ
(e) Random effects distribution. If we consider the tar-
get setting for the decision to be made up of those
included in the studies in the (network) meta-anal-
ysis, thenwewould expect heterogeneity estimated
in the (network) meta-analysis to be also seen in the
decision setting. Thismay be the casewhere there is
inherent variation between clinicians delivering
the treatments. It is then necessary to integrate
over the entire RE distribution in the CEA model
to obtain the net benefit for the decisionpopulation,
NBdecðk;dk; t; uÞ, which depends on the parameters
of the REdistribution. For example, for aNormal RE
model, dk;Nðdk; t2Þ, and
NBdecðk;dk ; t; uÞ5
ð
NB k; dk ; uð Þ 1
t
ﬃﬃﬃﬃﬃﬃ
2p
p e
dkdk
t
 2
ddk : ð8Þ
As in all cases above, the uncertainty in the parame-
ters fdk; t; ug must be averaged over to obtain the
expected net benefit.
Meta-Regression with Study-Reported Covariates
Allowing for covariates provides the potential to
explain some of the heterogeneity. Covariates can
include study characteristics, such as whether an
in- or outpatient setting was taken, and patient char-
acteristics, such as disease severity. Ideally, patient-
level data would inform estimation of patient covari-
ate effects, but in meta-analysis, it is often the case
that only study-level summaries are available. Let
xi; j be the observed value of covariate i reported in
study j, and then the network meta-analysis model
becomes10,11:
Fixed Effect Model :
dj;k;b5 ðdk 1
X
i
bi;kxi; jÞ  ðdb1
X
i
bi;bxi; jÞ; d15 0
Random Effects Model :
dj; k; b;Nððdk 1
X
i
bi; kxi; jÞ  ðdb1
X
i
bi; bxi; jÞ; t2Þ; d150
ð9Þ
where bi; k is the additional effect on treatment k com-
pared with treatment 1, per unit change in covariate i
and d1 = 0 (see above). If there are only two treatments,
then equation (9) reduces to a standard pairwise
meta-regression.11
Meta-Analysis Inputs to CEA in the Presence
of Covariates
The incorporation of covariates in an RE model
may reduce the heterogeneity parameter or even
reduce the RE model to an FE model in the extreme
case. Equations (2) to (8) can all be applied to the
resulting RE or FE model to obtain inputs to a CEA
model. However, some adjustments are required to
account for the covariates.
Binary covariates
Suppose covariate i is binary, for example,
whether the intervention is given in an in- or outpa-
tient setting. If the covariate is always present in the
decision setting, then the adjusted estimates
ðdk1bi; kÞ should replace dk in equations (2) to (8),
whereas if always absent, equations (2) to (8) are
unchanged. Suppose that we know from other data
sources that the covariate is present P% of the time,
then the net benefit defined in equations (2) to (8)
needs to be averaged over the covariate distribution:
P
100
NBdec k;dk 1bi;k ; u
 
1
100 P
100
NBdec k;dk 1bi;k ; u
 
:
ð10Þ
The uncertainty in the parameters fdk;bi; k; ugmust be
averaged over to obtain the expected net benefit.
Continuous covariates
Suppose covariate i is continuous, for example,
mean age or volume of operations undertaken per
year. If the value of the covariate in the target setting
for the decision is known (e.g., mean age is xdec), then
we replace dk with ðdk1bi; kxdecÞ in equations (2) to
HETEROGENEITY IN RELATIVE TREATMENT EFFECTS
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(8). If the value of the covariate is expected to vary
within the target setting for the decision—for exam-
ple, the distribution of the volume of operations
across hospitals may be known from national statis-
tics to be gðxdecÞ—then the net benefit defined in
equations (2) to (8) is an average over the covariate
distribution:
ð
NBdec k;dk 1bi; kx
dec; u
 
gðxdecÞdxdec: ð11Þ
The same approach applies for study-level ordinal
effect modifiers, but the integration is replaced by
a sum over all possible levels of the covariate.
Multiple covariates
Where there are multiple covariates x1; . . . ; xI,
the net benefit defined in equations (2) to (8)
needs to be averaged over the joint distribution
gðxdec1 ; . . . ; xdecI Þof those covariates in the decision set-
ting. For continuous covariates, this is
ððð
xdec1 ; ...;x
dec
I
NBdec k;dk 1
XI
i51
bi;kx
dec
i ; u
 !
gðxdec1 ; . . . ; xdecI Þdxdec1 . . .dxdecI : ð12Þ
The integration is replaced by a summation for binary
and ordinal covariates.
Heterogeneity in treatment definitions
Treatment definition is a common cause of hetero-
geneity (e.g., formulation, dose, timing, and duration
of treatment). Where there is a clinical rationale for
a differential effect across treatment definitions,
each distinct definition should ideally be considered
a separate treatment in a network meta-analysis
(equation (1)). However, this approach may lead to
an unconnected network of treatment comparisons,
and even if it is connected, theremaybeonly a limited
amount of evidence on each comparison. An alterna-
tive is to include aspects of the treatment definition
(e.g., dose) as covariates. This may be reasonable
where there is good evidence on the functional
dose-response relationship, with the potential to
increase precision of effect estimates. However, the
assumed relationship needs to be transparent and
fit to the data assessed. Another alternative is to con-
sider different groupings for the treatments, with
fixed or random treatment effect within group-
ing,10,15,16 and compare model fit to help aid the
choice of treatment definitions. For example, it could
be that doses within a particular range are
homogeneous but that very small or large doses lead
to differential treatment effects.
Risk of bias and small study effects
There is some evidence that treatment effects are
vulnerable to methodological flaws in study design
that introduce a risk of bias.17,18 For example, if the
randomization process in a trial is inadequately con-
cealed, selection bias may be introduced. There is
also evidence that treatment effects have a tendency
to be stronger in smaller studies.17,18 Risk of bias indi-
cators (e.g., whether randomization was adequately
concealed or not) can be included in a meta-
regression as binary or ordinal covariates, and the
treatment estimate used to inform cost-effectiveness
should be associated with studies at low risk of bias
(i.e., having adjusted for risk of bias) in the CEA
(i.e., set xdec= 0 and use dk in equations (2) to (8)).
Study size,Nj, can be treated as a continuous cova-
riate, usually modeled as either xi; j51=Nj or
xi; j51=
ﬃﬃﬃﬃﬃ
Nj
p
,19,20 so that an adjusted treatment effect
can be obtained by setting xdeci 5 0 (which corre-
sponds to lettingN ! ‘). If the relationship between
treatment effect and sample size observed in the
included studies can be assumed to continue as
N ! ‘, then this will provide a bias-adjusted treat-
ment effect estimate. However, the plausibility of
the extrapolation beyond the largest observed study
size should be considered.
Model Selection Strategy
The choice of covariates to include may in part be
driven bywhat is reported in the included studies but
should also be supported by clinical experts. There
may be several potential covariates for inclusion in
the meta-regression, and a strategy is required to
help choose between them. We propose the following
approach tomodel selection (although note there may
be other systematic approaches that can be taken):
Step 1 Fit FE and RE models with no covariates and
use model fit statistics and the estimated heterogene-
ity parameter, t, to choose between the models. If
there is no evidence of heterogeneity, then there is
no need to explore covariates. However, if there is
evidence of heterogeneity, then proceed to step 2.
Step 2 Fit the FEmodelwith each of the potential cova-
riates alone (i.e., univariable models), including dif-
ferent network meta-analysis structures to capture
heterogeneity in treatment definitions. Compare
model fit statistics to identify the key covariates that
explain some of the heterogeneity. For those key cova-
riates, also fit anREmodel.Note thatmodels including
WELTON AND OTHERS
612  MEDICAL DECISION MAKING/JULY 2015
 at Kings College London - ISS on August 24, 2016mdm.sagepub.comDownloaded from 
covariates may fit equally well to an REmodel without
covariates, but twill be lower if the covariate is explain-
ing someheterogeneity. If the FEmodelwith covariates
fits aswell as theREmodelwithout covariates, then the
covariates have explained the majority of the heteroge-
neity. Covariates for consideration should be guided by
clinical input as well as what information is available.
Step 3 Consider combinations of the key covariates
identified in step 2 by adding additional covariates
and comparing model fit statistics and t to identify
which combinations of covariates best explain the
heterogeneity.
Step 4 Report results from all of the best-fitting models
that achieve a similar model fit, and obtain clinical
input on the interpretation/justification of covariates
to help guide model choice. If necessary, repeat the
process in light of the clinical input.
If a Bayesian approach is taken, then the posterior
mean residual deviance and deviance information
criterion (DIC) measures21 for model fit and model
comparison can be used. If a frequentist approach is
used, then the deviance and Akaike information cri-
terion (AIC) measures22 can be used for model fit
and comparison.
ILLUSTRATIVE EXAMPLE: IVIG FOR SEVERE
SEPSIS AND SEPTIC SHOCK
Background and CEA Model
Sepsis is a syndrome characterized by a systemic
inflammatory response to infection that leads to rapid
acute organ failure and potentially rapid decline to
death. Severe sepsis (sepsis with acute organ dys-
function) represents approximately 31,000 patient
episodes and 15,000 in-hospital deaths per year in
the United Kingdom. Intravenous immunoglobulin
(IVIG), a human blood product, has been proposed
as an adjuvant therapy for severe sepsis, but evidence
regarding the use of IVIG in severe sepsis is conflict-
ing.23 We were commissioned to perform a system-
atic review, meta-analysis, CEA, and value-of-
information analysis of IVIG for severe sepsis and
septic shock, with an aim to assess the potential
value and design of additional primary research.14
A full description of the studies and the data that
were extracted is available in Tables 7 to 13 of this
report.14 The primary effectiveness outcome from
the RCT studies was all-cause mortality. The CEA
model, comparing IVIG with standard care, con-
sisted of a decision tree to model for short-term sur-
vival of a sepsis event and a Markov model for the
mid- to long-term consequences of surviving sepsis.
A meta-analysis of the RCT studies informed the rela-
tive effects of treatments on short-term mortality fol-
lowing a sepsis event. Other model inputs to the
CEA model came from a variety of registry and cohort
evidence sources (see report14 for full details). All pro-
grams and data available from NJW on request.
Potential Covariates in the Meta-Analysis of RCT
Studies
Treatment definitions
In the 17 identified RCT studies, IVIG was either
standard IVIG or IgM-enriched IVIG (IVIGAM) and
differed in the duration of treatment (days), daily
dose (g/kg21/d21), volume of fluid (mL/kg21/d21),
and total dose (g/kg21). Furthermore, there were sev-
eral different formulations. All studies had two arms
and used either albumin or no treatment (in addition
to standard treatment) as control. For the different
IVIG and control preparations, we considered 5 dif-
ferent possible treatment comparison models (num-
bered according to number of treatments), also
displayed in Figure 1:
Model T2: (IVIG or IVIGAM) v. (albumin or no
treatment)
Model T3a: IVIG v. IVIGAM v. (albumin or no
treatment)
Model T3b: (IVIG or IVIGAM) v. albumin v. no
treatment
Model T4: IVIG v. IVIGAM v. albumin v. no
treatment
Model T10: sandoglobin v. intraglobulin v. gamma-
venin v. polyglobin v. endobulin v. gamumin N v.
IVIG unspecified v. IVIGAMv. albumin v. no treatment
We initially explored extending the range of treat-
ment comparison models according to dosing regi-
men, but this did not always result in a connected
network. Instead, we considered the attributes of
the dosing regimen (average daily dose, volume,
duration, and total dose) as arm-level covariates.
We consider the simplest treatment model T2 as
the reference ‘‘no covariate’’ case (step 1) and explore
each of the other more complex treatment effect mod-
els in turn alongside the univariable models for the
other covariates (step 2). We have a preference for
the simplest treatment model that achieves adequate
fit (i.e., the most parsimonious).
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Risk of bias
We also extracted the following risk of bias infor-
mation: intention-to-treat analysis performed (yes/
no), concealment of allocation to treatment (ade-
quate/unclear/inadequate), blinding to treatment
(adequate/unclear/inadequate), randomization pro-
cedure (adequate/unclear/inadequate), Jadad score24
(which is based on a composite score for adequacy of
randomization [0–2 points], blinding [0–2 points],
and presence or absence of attrition information [0–
1 points], yielding a score from 0 to 5, where 5 repre-
sents the best quality score), publication date, and
sample size (intervention arm), which were consid-
ered potential covariates.
Other study characteristics
We also considered as covariates whether the
study reported that the trial was carried out in a criti-
cal care setting or not and follow-up period (weeks).
Patient characteristics
We included baseline risk (control arm log-odds of
mortality) as a covariate. Although other covariates
(such as scores for severity of illness and number
and sites of organ failure) were considered possible
effect modifiers, they were not reported in sufficient
detail in enough studies to be explored.
Model Selection
We used a Bayesian framework to fit the models
and assess model fit using the posterior mean resid-
ual deviance, Dres, which in a adequately fitting
model is expected to be approximately equal to the
number of data points if we assume normality (here
there are 2 3 17 = 34 data points for 17 two-arm stud-
ies). Models where Dres is much larger than this dis-
play evidence of lack of fit. For model comparison,
we also use the DIC, which provides a composite
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1
Figure 1 Network plots for each of the 5 treatment models considered. Treatments connected by a line indicate where randomized con-
trolled trial (RCT) evidence is available, and the width of the line is proportional to the number of RCTs making that comparison. IVIG,
intravenous immunoglobulin; IVIGAM, IgM-enriched IVIG.
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measure of model fit and model complexity, prefer-
ring models with lower DIC. Differences in Dres and
DIC of 3 or more are considered meaningful if we
assume normality.21 We also inspect changes in the
posterior mean of the between-studies standard devi-
ation, t, to observe howmuch heterogeneity has been
explained by introducing covariates.
Step 1: No covariates (model T2). The FE shows
substantial lack of fit (Dres = 51.4 compared with
34 data points), whereas the random effects model
fitted well (Dres = 30.9) (Table 1). This reflects the
high degree of heterogeneity (t = 0.56 on a log-
odds ratio scale; see also Figure 2).
Step 2:Univariablemodels (single covariates). The
key covariates that appeared to explain some of the
heterogeneity in the meta-analysis were dosing regi-
men covariates (duration of treatment, daily dose,
and volume), treatment definition (T3b was the
most parsimonious), and risk of bias covariates
(Jadad score, publication date, and a measure of
sample size: 1 =
ﬃﬃﬃﬃ
N
p
) (Table 1). Including any one
of these key covariates resulted in reduction in
Dres and DIC in the FE model and a reduction in t
in the RE model. Further improvement in model fit
was obtained by treating each IVIG preparation as
a separate treatment (T10); however, this model
was more complex, and on the basis of DIC, model
T3b was preferred. Follow-up period showed
a mild effect, but this disappeared when any of the
above key covariates were included (results
omitted).
Step 3: Multivariable models (combinations of key
covariates). There was no improvement in model fit
from including all key dosing regimen covariates
compared with including just one (Table 2). Simi-
larly, for the ‘‘risk of bias’’ covariates, it was only
considered necessary to include one of these covari-
ates in further models (Table 2). Combining a dosing
regimen covariate with a risk of bias covariate
improved model fit and led to reductions in DIC
(Table 2). This suggests that these two types of cova-
riates measure different aspects of heterogeneity.
Furthermore, for treatment model T3b, adding risk
of bias covariates did not lead to much change in
model fit, suggesting that the choice of control
explains the same aspect of heterogeneity as the
risk of bias covariates (Table 2). The FE models
that give the lowest DIC are highlighted in bold in
Table 1 Model Selection Steps 1 and 2
Covariate Type Covariate
FE RE
Dres DIC Dres DIC t
None No covariates (Model T2) 51.4 188.2 30.9 175.0 0.56
Dosing regimen Duration of treatment (days) 37.1 175.0 32.5 175.3 .38
Daily dose (g/kg21/d21) 36.9 174.6 33.0 175.2 .36
Volume (mL/kg21/d21) 36.9 174.6 33.2 175.3 .36
Total dose (g/kg21) 52.2 190.0
Treatment model T3a 50.1 187.9
T3b 42.8 180.5 31.6 175.3 0.48
T4 43.6 182.3
T10 36.2 180.7
Risk of bias Intention-to-treat analysis (yes/no) 45.0 182.7
Adequacy of concealment of allocation to treatment 41.5 179.2
Adequacy of blinding to treatment 48.8 186.5
Adequacy of randomization procedure 45.2 182.9
Jadad score 39.2 176.9 32.2 175.6 .45
Publication date 35.9 173.7 33.1 174.8 .31
1=
ﬃﬃﬃﬃ
N
p
(N = number of patients randomized to IVIG arm) 36.6 174.4 32.7 174.6 .33
Other Critical care setting 51.6 189.4
Baseline risk (control arm log-odds of mortality) 53.0 190.8
Follow-up period (linear relationship) 46.5 184.3
Follow-up period (\4 or 4 weeks) 48.5 186.3
Summaries of model fit beginning with the 2-treatment comparison model (model T2: (IVIG or IVIGAM) v. (albumin or no treatment)) and then adding
single covariates individually. Different treatment models (in the absence of other covariates) are also compared. Summary statistics are the posterior
mean residual deviance, Dres; the deviance information criterion, DIC; and the posterior mean of the between-trials standard deviation, t. Key covariates
that substantially improve model fit are highlighted in bold. For treatment models, where fit is comparable, the simplest model is highlighted. IVIG, intra-
venous immunoglobulin; IVIGAM, IgM-enriched IVIG; FE, fixed effects; RE, random effects.
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Table 2. The best-fitting FE model (and lowest DIC)
was obtained for treatment model T3b with duration
of treatment as a covariate (Table 2). This model fit-
ted as well as the RE model with no covariates
(Tables 1 and 2), suggesting that for this example,
there are two dimensions of heterogeneity, one relat-
ing to the dosing regimen and the other to risk of
bias.
Step 4: Incorporation of expert opinion and sensi-
tivity analyses. We found that aspects of treatment
regimen (duration of treatment, daily dose, volume)
were associated with treatment effect. However,
discussions with the expert advisory group for the
project highlighted that there was no clinical mech-
anistic rationale why these aspects of treatment reg-
imen would affect treatment effects across the ranges
examined within the included studies. Because
these aspects of treatment regimen were not com-
pared within studies, there was the worry that the
effects we had observed were subject to ecological
bias, highlighting the lack of early phase studies
for IVIG for severe sepsis and septic shock. In partic-
ular, studies with longer duration of treatment may
reflect a healthier population that could be treated
for longer. The expert advisory group agreed that
risk of bias indicators were important covariates to
include and that the choice of control could be
a proxy for risk of bias because albumin resembles
IVIG, indicating adequate blinding. We therefore
report results from RE models with one key risk of
bias covariate as a sensitivity analysis, in addition
to results of the best-fitting model (FE model T3b
with duration of treatment as a covariate). In these
RE models, the heterogeneity that can be explained
Overall  (I−squared = 47.0%, p = 0.017)
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Tugrul 2002
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Figure 2 Forest plot for (IVIG or IVIGAM) v. (albumin or no treatment). Random effects model. IVIG, intravenous immunoglobulin; IVI-
GAM, IgM-enriched IVIG.
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with the dosing regimen covariates was left unex-
plained, reflecting a belief that these covariates
were a proxy for other, unmeasured, differences
between the studies.
Results from Meta-Analysis
Table 3 shows the results from the models identi-
fied in the model selection process. Results are
reported for albumin as the comparator for treatment
model T3b and for the following covariate values: dura-
tion = 3 days (in the absence of any other rationale, 3
days was the most commonly reported treatment dura-
tion in the included studies), Jadad score = 5 (least risk
of bias), publication date = 2007 (most recent in
included studies), sample size N ! ‘ (infinitely large
study), and N5339 (the sample size for the IVIG arm
of the largest of the included studies).
For the REmodels, there are a variety of options as
to the relevant predicted treatment effect to report
and use in CEA (options (a)–(e) above). No single
study or subsets of studies were considered more rel-
evant than the others to the decision setting, and so
options (c) to (d) were not appropriate. There was
no reason to expect that the heterogeneity between
studies was inherent variability (e.g., between
hospitals/centers) that would be experienced in
a roll-out of the intervention, and so option (e) was
not considered appropriate. As described above,
the random effects mean, option (a), is unlikely to
be a good summary in general, and so we report
results from the predictive distribution, option (b),
which reflects the additional uncertainty resulting
from the unexplained heterogeneity. For compari-
son, we report both options (a) and (b) for the RE
T3b model.
The results show that the uncertainty in the treat-
ment effect estimate is smallest for the FE T3b model
with duration as a covariate (Table 3). For the RE
model T3b, the uncertainty in the treatment effect
estimate ismuchwider for the predictive distribution
compared with the RE mean summary (Table 3).
The results are highly sensitive to the choice of
model, with predicted odds ratios ranging from 0.6
(IVIG beneficial), for an RE T3b model reporting the
RE mean, to 1.27 (IVIG harmful), for the RE T2 model
withN ! ‘ (albeitwith verywide credible intervals).
However, note that the predictions from this model
involve an assumption that the relationship between
treatment effect and sample size continues for sample
sizes beyond the observed studies. The results with
publication data and Jadad score are very similar,
Table 2 Model Selection Step 3
Covariates
Model T2 Model T3b
Dres DIC Dres DIC
Duration of treatment (days) 37.1 175.0 29.8 168.6
Daily dose (g/kg21/d21) 36.9 174.6 37.4 176.2
Volume (mL/kg21/d21) 36.9 174.6 37.5 176.3
T3b 42.8 180.5
Jadad score 39.2 176.9 39.3 178.1
Publication date 35.9 173.7 36.4 175.2
1=
ﬃﬃﬃﬃ
N
p
(N = number of patients randomized to IVIG arm) 36.6 174.4 36.1 174.9
Duration of treatment 1 daily dose 1 volume 34.3 173.6 30.8 171.3
Jadad score 1 publication date 1 1=
ﬃﬃﬃﬃ
N
p
35.7 175.4 36.7 177.6
Duration of treatment 1 Jadad score 33.4 172.3 30.7 170.5
Duration of treatment 1 publication date 31.4 170.2 30.1 169.8
Duration of treatment 1 1=
ﬃﬃﬃﬃ
N
p
33.7 172.5 30.7 170.5
Daily dose 1 Jadad score 37.4 176.2 38.0 177.7
Daily dose 1 publication date 34.6 173.3 35.6 175.4
Daily dose 1 1=
ﬃﬃﬃﬃ
N
p
32.2 171.0 33.1 172.9
Volume 1 Jadad score 37.5 176.3 38.1 177.8
Volume 1 publication date 34.7 173.4 35.7 175.5
Volume 1 1=
ﬃﬃﬃﬃ
N
p
32.4 171.2 33.3 173.1
Summaries of model fit for fixed effects models with combinations of the key covariates identified in steps 1 and 2 (Table 1). Summary statistics are the
posterior mean residual deviance, Dres, and the deviance information criterion, DIC. Best-fitting models are highlighted in bold. IVIG, intravenous
immunoglobulin.
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and since it is easier to justify making predictions for
Jadad score = 5 than for a publication date of 2007, we
use the model with Jadad score and not publication
date in the CEA models.
Results from the CEA and Value-of-Information
Analysis
The results from the CEA were highly sensitive to
the choice of model (Table 4), with the incremental
cost-effectiveness ratio (ICER) ranging from £15,000
to IVIG being dominated. The optimal decision
depends on the model used, especially for the
£20,000 threshold. There is considerable uncertainty
in the optimal treatment under all models, with the
probability that IVIG is cost-effective at the £20,000
threshold ranging from 0.3 to 0.7, with the RE mean
givingmore certainty than the predictive distribution
for model RE T3b (Table 4). The expected value of
information for all parameters (EVPI) and for the rel-
ative effect parameters (EVPPI) indicate that, regard-
less of the model used, there is substantial potential
value in new research, including a well-conducted
RCT comparing IVIG with standard care (Table 4).
However, the optimal design of such a study is highly
sensitive to the model selected (Table 4), ranging
from 800 to 1900 per arm.
DISCUSSION
We have presented a structured model selection
strategy to incorporate covariates in evidence
synthesis of relative treatment effects and described
different model summaries that can be used as inputs
to CEA models, depending on how the heterogeneity
in the evidence relates to the setting for the decision.
Applying the methods to our illustrative example
allowed us to identifymodels that eliminated the het-
erogeneity to an FE model through the inclusion of
covariates, although we also presented results from
RE models after incorporating expert opinion. There
have been several previous meta-analyses conducted
on IVIG for severe sepsis/septic shock,25–30 and con-
flicting conclusions have been drawn.23 Although
all previous meta-analyses tested for heterogeneity,
all (with the exception Turgeon et al.27) performed
a fixed effects meta-analysis. Our findings from uni-
variate analyses are in concordance with findings
from previous meta-analyses, but our meta-analysis
is the first to simultaneously allow for type of IVIG/
IVIGAM, control treatment, study quality/publica-
tion bias, dosing regimen, and other potential covari-
ates. Without exploring the model space fully and
integrating expert input, the sensitivity of results to
choice of model and interpretation of that model
may be missed.
We found that clinical input is essential to obtain
results that are interpretable and to help choose
between competing models that fit equally well. In
our illustrative example, the expert opinionwas valu-
able tomake uswary of overinterpretation of the best-
fitting FE models, which included aspects of treat-
ment regimen; present results from other models
that do not include treatment regimen covariates;
and help us understand the difference between
Table 3 Predicted Odds Ratio (95% Credible Intervals) for the Best-Fitting FE Model T3b
with Duration of Treatment as a Covariate and for RE Models with a Key Risk of Bias Covariate
(Reporting the Predictive Distribution, Option b)
Treatment Model Covariate Reports Predicted OR (95% Credible Intervals)
FE T3b Duration IVIG v. albumin for duration = 3 days 0.75 (0.58, 0.96)
RE T3b None IVIG v. albumin predictive distribution
(option b)
0.68 (0.16, 1.83)
RE T3b None IVIG v. albumin RE mean (option a) 0.60 (0.32, 0.95)
RE T2 Jadad IVIG v. control predictive distribution
(option b) for Jadad score = 5
0.83 (0.18, 2.13)
RE T2 Publication date IVIG v. control predictive distribution
(option b) for publication date = 2007
0.83 (0.24, 1.72)
RE T2 1=
ﬃﬃﬃﬃ
N
p
IVIG v. control predictive distribution
(option b) for N ! ‘
1.27 (0.25, 3.17)
RE T2 1=
ﬃﬃﬃﬃ
N
p
IVIG v. control predictive distribution
(option b) for N 5 3 3 9
0.92 (0.23, 2.10)
For illustration, results reporting the RE mean (option a) are presented for the RE model T3b. IVIG, intravenous immunoglobulin; FE, fixed effects; RE,
random effects; OR, odds ratio.
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treatment definitions, particularly the difference
between the no treatment and albumin controls,
and the link with risk of bias. Of course, expert opin-
ion may also be subject to cognitive biases,31,32 such
as confirmation bias, and in panels of experts the
‘‘bandwagon effect.’’
We have proposed a particular model selection
strategy, but other structured approaches could
have been taken. To explore the relative performance
of different selection strategies would require
a detailed simulation study, which is an area for fur-
ther research. When there is no other rationale to
choose betweenmodels, sensitivity analysis is essen-
tial. Model averaging could be used to obtain
a weighted analysis over the plausible model
space.33,34 A fully Bayesian approach could also use
expert opinion to obtain prior model weights for dif-
ferent covariate models. However, model averaging
does not help with the interpretation and under-
standing of causes of heterogeneity and, as such,
does not deliver any advantage over a simple RE
model with no covariates.
Heterogeneity in treatment definition is common,
and treatments are often grouped together (e.g., over
dose or treatment class). Our approach can help
determine whether grouping together is reasonable,
again with clinical input. For IVIG, it was found to
be reasonable to group treatments across different
IVIG preparations. However, dosing regimen led to
treatment effect modification and must be included
as a covariate or as unexplained heterogeneity in an
RE model. It was concluded that basic science was
needed to better understand the mechanism of action
of IVIG and to determine appropriate dosing regi-
mens through dose-ranging studies.14,35
Risk of bias information is routinely collected, but
we are unaware of other examples where bias adjust-
ment has been used in CEA. We found that sample
size was an important covariate. The natural way to
adjust for bias due to small study effects is to predict
the treatment effect as N ! ‘. Results were highly
sensitive to this because if the relationship observed
between treatment effect and sample size in the
included studies were to continue as N ! ‘, then
we predict that IVIG is harmful, albeit with high
uncertainty. It is likely that IVIG is not considered
likely to be harmful (otherwise the RCTs would not
have been conducted), and so one possible solution
would be to use an informative prior that gives rela-
tively low weight to treatment effects that are harm-
ful. This would need to be elicited from clinical
experts.
We have usedmeta-regression methods to identify
effect modifiers, but these methods suffer from low
power to detect effects and are vulnerable to ecologi-
cal bias.6 This is especially the case in the (common)
situation where the spread of covariate values across
studies is sparse (e.g., only a few studies where the
covariate is absent). It was not possible to explore
potential covariates where the data were sparse,
Table 4 Results from the Cost-Effectiveness Model14 for the Best-Fitting FE Model T3b
with Duration of Treatment as a Covariate and for RE Models with a Key Risk of Bias Covariate
(Reporting the Predictive Distribution, Option b)
Model
ICER (IVIG
v. Standard)
Prob(CE),
£20,000
Threshold
Prob(CE),
£30,000
Threshold
Pop. EVPI
(10-y Time
Horizon)
Pop. EVPPI
(Relative
Effects)
Optimal
Sample
Size, n*
ENBS
at n*
FE T3b, duration = 3 days £20,850 0.505 0.789 £393m £174m 1900 £137m
RET3b, IVIG v. albumin. predictive
distribution (option b)
£16,177 0.597 0.707 £1017m £718m 1200 £687m
RE T3b, IVIG v. albumin. RE mean
(option a)
£15,488 0.721 0.871 £472m £148m 1400 £116m
RE T2, Jadad = 5, predictive
distribution (option b)
£19,968 0.502 0.611 £1367m £1022m 800 £1011m
RE T2, 1=
ﬃﬃﬃﬃ
N
p
(N = 339), predictive
distribution (option b)
£28,520 0.404 0.514 £898m £620m 900 £606m
RE T2, 1=
ﬃﬃﬃﬃ
N
p
(N ! ‘), predictive
distribution (option b)
Dominated 0.275 0.348 £603m £381m 800 £365m
For illustration, results reporting the random effects (RE) mean (option a) are presented for the RE model T3b. Results reported are the incremental cost-
effectiveness ratio (ICER) for IVIG v. standard care; the probability that intravenous immunoglobulin (IVIG) is cost-effective, Prob(CE), at the £20,000 and
£30,000 willingness-to-pay per quality-adjusted life year thresholds; the total population expected value of perfect information (EVPI); the population
expected value of partial perfect information (EVPPI) for the relative treatment effect parameters; the optimal sample size of a new trial, n*, that maximizes
the expected net benefit of sampling (ENBS); and the ENBS obtained at n*.
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although these may have been important treatment
effect modifiers. Individual participant data (IPD)
avoid many of these problems, although it may not
be possible to obtain IPD from all (or any) of the
included studies. There has been some recent work
on methods for the combination of studies where
there is IPD available for some but not all studies on
a binary outcome.36 However, there is no real
substitute for IPD when continuous patient-level
characteristics are important effect modifiers. One
important potential treatment effect modifier is base-
line risk. We found that including baseline risk as
a covariate in our example did not improve model
fit (results omitted). Note that by modeling relative
effects on the log-odds scale already imposes an inter-
action between baseline risk and relative effects on
the absolute probability scale (with smaller absolute
probability differences when baseline probability is
close to 0 or 1), which perhaps explains why there
was no added benefit of explicitly using baseline
risk as a covariate. Careful attention needs to be given
to the scale on which the model acts and an aware-
ness of what this implies in terms of interactions on
an absolute scale.
We have assumed that there is a single effective-
ness parameter that inputs to the CEAmodel. In prac-
tice, theremay bemultiple outcomesmeasured in the
studies included in the meta-analysis (e.g., all-cause
mortality, risk of stroke and bleeds), and these may
be correlated. Multivariate meta-regression models37
across outcomes will therefore be required. Methods
for model selection with multiple outcomes and how
the results from these models can be used in CEA is
an area for further study.
We have focused on heterogeneity in relative treat-
ment effects, but there may be heterogeneity in other
inputs to a CEAmodel. In particular, heterogeneity in
natural history parameters, such as baseline risk, is
likely. Ideally, large cohort studies or registry data
representative of the decision setting would be used
to estimate baseline risk38 and relative effects from
the evidence synthesis applied to the baseline risk
to obtain absolute risk for use in the CEA model.
Where subgroups according to baseline risk can be
identified, then CEA results can be broken down by
subgroup to give tailored treatment recommenda-
tions, or the subgroups can be averaged over to give
a population average treatment recommendation, as
described in equations (10) to (12). In the absence of
relevant cohorts or registries, the ‘‘standard care’’
arms from the RCTs included in a meta-analysis or
network meta-analysis that are considered represen-
tative of the decision setting may be used to estimate
baseline risk. To avoid introducing bias in the relative
treatment effects, a synthesis of the ‘‘standard care’’
arms should be done in a separate analysis from the
synthesis of the relative treatment effects.38 All of
the ideas presented in this article extend naturally
to a synthesis of standard care arms to estimate base-
line risk and also to any other model inputs that may
exhibit heterogeneity.
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